Please login to the form below
Editas Medicine names James Mullen as chairman
He has previously served as CEO of Patheon
Genome editing company Editas Medicine has appointed James Mullen as chairman of the board of directors.
Mullen has over 30 years’ experience leading biotechnology and pharmaceutical organisations on a global scale.
Previously, Mullen has served as chief executive officer of Patheon, a pharmaceutical development and manufacturing services provider, until its acquisition by Thermo Fisher Scientific last year.
Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.
Katrine Bosley, president and chief executive officer of Editas Medicine, said: “Jim is a renowned leader in the biotechnology industry with deep experience building global companies and guiding corporate strategy, and I am very pleased to welcome his as chairman of the board.
“Jim’s extensive experience in driving excellence across R&D, commercialisation, manufacturing, business development and capital formation will be invaluable as we continue to build a genomic medicine leader and develop medicines for patients in the years to come.”
In addition, the company announced that Alexis Borisy and John Mendlein stepped down from the board.
COVID-19 Updates and Daily News
Featured jobs
-
Head of Copy
-
£ competitive
- Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies
- Pfizer CEO announces plans to launch Omicron-specific COVID-19 vaccine
- Pfizer expands access to lipid nanoparticle technology in new agreement with Acuitas Therapeutics
- Biogen’s Alzheimer’s treatment Aduhelm limited to clinical trial participants in the US
- BMS and 2seventy bio move away from CAR-T programme
- Amgen’s Lumykras receives conditional marketing authorisation from EC
- Live Webinar: Expanding Access to High-Quality Healthcare
- Vir Biotech launches new research programme for HIV and malaria prevention
- BioNTech and InstaDeep collaboration develops SARS-CoV-2 Early Warning System
- After the wildfire: how will healthcare recover from the pandemic?
- The New Normal: Upcoming Trends in Clinical Trials
- Why pharma must get smart in its approach to customer engagement
- Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Amgen’s Lumykras receives conditional marketing authorisation from EC
- FDA approves Roche’s Actemra COVID-19 trial
- J&J’s COVID-19 booster shows 85% effectiveness in preventing hospitalisation for COVID-19 in study
- Pfizer, BioNTech’s COVID-19 vaccine prevents 90% of infections in initial late-stage study data
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- The doctor will text you now: Why healthcare providers cannot underestimate the importance of communicating change
- Healthcare communication needs to switch from ‘transmit’ to ‘receive’, listening to what patients need and embracing the plethora of communication tools wholeheartedly....
- How to innovate and influence people in times of misinformation
- The pandemic has shown that public trust in promising new medical technologies is far from a given. Senior Writer Tom Vandyck at StoneArch, a member of Fishawack delves into the...
- Could femtech be the answer to the gender health gap?
- Here, we discuss the phenomenon of femtech, an industry that puts women’s experiences of lifestyle and health front and centre. We highlight some of the major players in the industry,...
